Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2022-08-18 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于健帆HA130血液灌流器联合血液透析改善维持性血液透析患者生存质量前瞻、随机、对照的多中心临床研究成果在国际权威医学杂志《Blood Purification》发表的自愿性信息披露公告
Regulatory Filings Classification · 95% confidence The document is a voluntary information disclosure announcement by the company about the publication of clinical research results in an international medical journal. It details the study, its results, and the significance for the company and industry. The document is relatively short (2517 characters) and does not contain financial statements or detailed financial analysis. It is an announcement of research publication and its potential impact, not a financial report or regulatory filing. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not fit other specific categories.
2022-08-18 Chinese
关于控股子公司取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding its controlling subsidiary obtaining a medical device registration certificate. It includes details about the product, registration number, validity, and potential impact on the company. There are no financial statements, no mention of quarterly or annual results, no voting results, no management changes, no merger or acquisition activity, and no regulatory certifications or attestations. The document is relatively short (947 characters) and serves as a formal announcement of a regulatory approval related to product registration. This fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2022-07-25 Chinese
独立董事关于第四届董事会第三十六次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters discussed at the 36th meeting of the 4th board of directors of a company. It addresses issues such as project delays, use of idle raised funds for cash management, and bank credit applications. The content is related to board-level decisions and independent directors' assessments rather than financial results, audit reports, or regulatory filings. It does not contain financial statements or earnings data, nor is it a report publication announcement. The document fits best under Board/Management Information (MANG) as it concerns board meeting matters and independent directors' opinions on company governance and financial management decisions.
2022-07-19 Chinese
关于向银行申请综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by the company regarding its application for a comprehensive credit facility from banks, specifying the amount, purpose, and approval by the board of directors. It includes details about the credit limit, duration, and the board meeting resolutions approving the application. There are no financial statements, earnings data, or detailed financial analysis present. The document is an update on financing activities rather than a full financial report or earnings release. It is not a report publication announcement since it contains substantive information about the financing decision. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is short and focused on the financing announcement, confirming this classification with high confidence.
2022-07-19 Chinese
关于部分募投项目延期的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the delay of certain fundraising investment projects. It details the progress of the projects funded by previously raised convertible bonds, reasons for the delay, and approvals from the board, independent directors, and supervisory board. The document does not contain financial statements or detailed financial results but is an update on the status of capital use and project timelines. It is not a full financial report, earnings release, or audit report. It is a specific update related to capital projects and fundraising usage, which fits the category of Capital/Financing Update (CAP). The document length is about 3200 characters, which is consistent with an announcement rather than a full report. Therefore, the best classification is CAP with high confidence.
2022-07-19 Chinese
第四届董事会第三十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of 健帆生物科技集团股份有限公司 on July 19, 2022. It details the meeting attendance, voting results, and specific agenda items such as project delays, use of idle funds for cash management, and application for a bank credit line. The document does not contain financial statements or detailed financial analysis but rather reports on board decisions and approvals. It also references related announcements published separately on a regulatory disclosure website. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board or senior management. The document length is short (1398 characters), and it is not a report publication announcement or a certification. Therefore, the appropriate classification is MANG with high confidence.
2022-07-19 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.